Role of Neutrophil to Lymphocyte Ratio (NLR) as an Early Predictor of Mortality in Critically Ill Patients
International Journal of Current Pharmaceutical Review and Research · 31.03.2026 · 18 (03)
DOI: 10.25258/ijcpr.18.3.268 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Current Pharmaceutical Review and Research, online erschienen am 31.03.2026. Verfasst von Rajesh Raushan und 4 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Early identification of high-risk patients is crucial for improving outcomes in the intensive care unit (ICU). The neutrophil-to-lymphocyte ratio (NLR), derived from routine blood tests, is a simple inflammatory marker that may predict mortality in critically ill patients.
Aim
To evaluate the predictive value of NLR for mortality in critically ill ICU patients.
Methods
This retrospective observational study included 200 critically ill patients admitted to the ICU over a period of 6 months. NLR was calculated from admission blood samples. Patients were categorized into two groups: low NLR (
Zitieren
APA
Raushan, R., Kumar, S., Qamar, T., Kumar, N., & Imam, A. (2026). Role of Neutrophil to Lymphocyte Ratio (NLR) as an Early Predictor of Mortality in Critically Ill Patients. International Journal of Current Pharmaceutical Review and Research, 18(03). https://doi.org/10.25258/ijcpr.18.3.268
Vancouver
Raushan R, Kumar S, Qamar T, Kumar N, Imam A. Role of Neutrophil to Lymphocyte Ratio (NLR) as an Early Predictor of Mortality in Critically Ill Patients. International Journal of Current Pharmaceutical Review and Research. 2026;18(03). doi:10.25258/ijcpr.18.3.268
BibTeX
@article{Raushan2026,
author = {Raushan, Rajesh and Kumar, Sanjeev and Qamar, Tanweer and Kumar, Niranjan and Imam, Adnan},
title = {Role of Neutrophil to Lymphocyte Ratio (NLR) as an Early Predictor of Mortality in Critically Ill Patients},
journal = {International Journal of Current Pharmaceutical Review and Research},
year = {2026},
volume = {18},
number = {03},
doi = {10.25258/ijcpr.18.3.268}
}
EUVIMED